Expanded R&D facility opens at Cubist headquarters

NewsGuard 100/100 Score

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the official opening of its expanded research and development facility at its headquarters at 65 Hayden Avenue in Lexington, Massachusetts. The 104,000 square-foot expansion includes state-of-the art laboratory space for research and development around antibiotics and other acute care products, a molecular modeling room, office space, and conference rooms. Built to the LEED Silver Standard, the building features high efficiency plumbing and lighting fixtures, distribution controlled heating and cooling systems, and updated mechanical equipment and Energy Star-rated appliances.

“My priority in the Senate is to support job creators like Cubist in order to create more opportunities for hiring here in Massachusetts.”

Cubist held an official opening ceremony for the R&D facility earlier today, with speakers including company President and CEO Michael Bonney and special guest U.S. Senator Scott Brown.

"As we celebrate our 20th anniversary this year, it is our belief that this state-of-the-art R&D facility will be at the center of a wave of future growth and innovation for Cubist," said Mr. Bonney. "We look forward to many years of translating exciting science into real therapeutic options for patients in the acute care and hospital environment."

"Innovative companies like Cubist Pharmaceuticals are on the leading edge of job creation in Massachusetts," said Senator Brown. "My priority in the Senate is to support job creators like Cubist in order to create more opportunities for hiring here in Massachusetts."

Source:

Cubist Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses